Plus BMS and J&J get dealt a district court defeat in their IRA cases
And we're about halfway through earnings season, with the big obesity-med companies reporting this week
Vertical integration by big insurance companies is going to break my brain
And why Bernie's latest crusade is likely to be all heat, no light
And some thinking on the math being used to estimate the impact of obesity meds in Medicare
And I'm conflicted about a sprawling white paper on gene therapy pricing and access
And Takeda in the 8th company to drop data on its list- and net-price changes for 2023
And there are new 340B dispute resolution rules out for you true wonks
Plus a fiery BioCentury piece that celled a recent JAMA analysis of accelerated approval 'intellectual malpractice'
Plus more good news for obesity drugs, which is bad news for those who question the meds' value
Plus extended thoughts on the intersection between a GAO report, insulin legislation, and the weird state of Humira biosims
And CF Treatment Has Come So Far That Make-a-Wish Won't Automatically Accept Wishes from Those With CF
